Delivery Order SPE2DR25D1017-SPE2DR26F8YRL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,131.67 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units), a diabetes medication. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded and due for completion by August 1, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,267.45 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pen (0.5 mL), a diabetes medication. The contract is firm fixed price with no set-aside designation and carries an ultimate completion date of April 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,601.07 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pen (0.5 mL), a diabetes treatment medication. The contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. This award was made on a competitive basis with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen (0.5 ml), a diabetes medication. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The contract was awarded on October 21, 2025, with an ultimate completion date of October 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL), a diabetes medication. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition. This...
- The Defense Logistics Agency awarded a $1,632.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen (0.5 ml), a diabetes medication. The order was competitively awarded with no set-aside designation and is scheduled for completion by October 27, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance, aligning with the company's role as a primary pharmaceutical distributor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,897.78 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pens (a diabetes medication) on September 3, 2025, with a completion date of September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a relatively small transaction within...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,635.27 for Mounjaro 5 mg/0.5 mL pen (0.5 mL), a diabetes medication, with an ultimate completion date of July 15, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $1,249.48 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen (0.5ml), a diabetes medication. The contract, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, was competitively awarded with no set-aside designation and employs firm fixed-price pricing. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,641.17 for Mounjaro 7.5 mg/0.5 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single shipment of this diabetes medication to support federal medical...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F8YRLDelivery Order
The Defense Logistics Agency has awarded a delivery order valued at $2,370.78 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pens (0.5 ml), a diabetes treatment medication. This is a firm fixed-price delivery order with an ultimate completion date of October 30, 2025, and was competitively awarded without any set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor for the federal government, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contracts demonstrates its capability to distribute specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to meet defense and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 10/29/25 |